Biobytes

The World's First Multicenter Biobank Dedicated to Sarcopenia

Using our proprietary sarcopenia biobank,Biobytes discovers biomarkers for drug development.

By integrating genomic and transcriptomic analysis,we prioritize evidence-based targets and maximize the potential for drug development success.

Pipeline

Sarcopenia(Small Molecule)

In-House

  1. Basic Research
  2. Candidate Discovery
  3. Preclinical Study
  4. Phase I
  5. Phase II
  6. Phase III

Sarcopenia(bioPROTAC)

Joint Research

  1. Basic Research
  2. Candidate Discovery
  3. Preclinical Study
  4. Phase I
  5. Phase II
  6. Phase III

Sarcopenia(Antibody)

Joint Research

  1. Basic Research
  2. Candidate Discovery
  3. Preclinical Study
  4. Phase I
  5. Phase II
  6. Phase III

MASH/MASLD

In-House

  1. Basic Research
  2. Candidate Discovery
  3. Preclinical Study
  4. Phase I
  5. Phase II
  6. Phase III

Advancing Drug Development with Biobytes

Biobank cohort data accelerates evidence-based drug development.

Contact Us